Our technology is powered by SNO-pods™

Your sustainable NO solution

Our research team developed and investigated a next-generation microparticle that is suitable for clinical translation. This new technology is scalable, consistently delivers NO at high flow-levels and can be packaged in a simple and shelf-stable format. The microparticles themselves are small enough (~3 µm) to be readily imbedded into the stratum corneum, but not so small that they penetrate into viable tissue.

​

The product concept requires a dual-component package that has a Component A and a Component B. Component A and Component B contain stable precursors for the formation of NO, including thiolated silica microparticles (Thiol-MP).  

At the desired time of administration, the end-user breaks the seal that separates the two white-colored components and commingles them, effecting the rapid formation of NO, which causes the commingled formulation to turn pink. 

Thiol-MP acts to harness this NO such that, when the product is applied to the skin, it releases it into local tissue in a controlled fashion rather than a bolus release of free NO.

Great strides have been made in the development of both Thiol-MP and the dual-component formulation. The harnessing of NO for topical administration is an important achievement as NO typically exists as a reactive gas available only in pressurized-cannister form.